Home » Author Archive

About: James A. Datin

James A. Datin

Jim Datin is Executive Vice President and Managing Director of the Deal Team at Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital and operational support for entrepreneurial and innovative life sciences and technology companies. At Safeguard, Jim applies his more than 25 years of experience to drive Safeguard’s partnership opportunities for both the life sciences and technology groups, which focus on molecular and point-of-care diagnostics, medical devices, regenerative medicine, specialty pharmaceuticals and selected healthcare services; and Internet / New Media, Financial Services IT, Healthcare IT and selected business services, respectively.

Over the course of his career, Jim has completed more than 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements. He has been a successful CEO, raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia.

Prior to Safeguard, Jim was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA.

Jim is a former board member of Intralinks, where he chaired the audit committee and filed the company’s SEC Form S-1 for its initial public offering. The company was acquired by TA & Associates, a large private holding firm, for more than $430 million, representing a 6x return to investors.

Jim currently is a member of the board for Safeguard’s partner companies NovaSom and Putney. In addition, Jim is on the Executive Board for Celerant Consulting; the Life Science Investment Advisory Committee for Ben Franklin Technology Partners of Pennsylvania; the Advisory Board for Sanofi Aventis, the board for Hepatitis B Foundation; and is Vice Chairman of the board for the University City Science Center in Philadelphia. He is a NASDAQ accredited and certified board member.

The Power of emPower!

The Power of emPower!

Posted by James A. Datin on November 21, 2011
0
PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and powered by tiny microelectronics hidden inside the frames, providing...

Continue Reading »

Opportunity in the Migraine Market for NuPathe
1
Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that are administered orally are less effective. Enter Zelrix, or NP101, which...

Continue Reading »

Anatomy of a Deal: Advanced BioHealing
0
Last week our own Gary J. Kurtzman, MD, Senior Vice President and Managing Director in the Safeguard Life Sciences Group, participated on a panel at the Southeast BIO Investor Forum in North Carolina that featured “The Story of Shire’s Acquisition...

Continue Reading »

The Developing Pet Generics Market: A Look at New Partner Company Putney
0
In America, there are more than 171 million dogs and cats in over 71 million households. Ninety-six percent of the drugs approved for these pets are not generic, whereas 78 percent of prescriptions filled for humans are. New partner company Putney has...

Continue Reading »

Safeguard Scientifics Leads $35 Million Financing for NovaSom
1
Baltimore-based company provides home sleep tests for the diagnosis of obstructive sleep apnea Wayne, PA, June 27, 2011 – Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies,...

Continue Reading »

Life Sciences Trends for 2011: Companion Diagnostics, Reimbursement and Consumerization
1
Last week, Safeguard Scientifics’ Life Sciences team attended J.P. Morgan’s 29th Annual Healthcare Conference and OneMedForumSF 2011 (video) in San Francisco. Our main takeaway is that the healthcare industry is still alive. From an investment...

Continue Reading »